Compare Hasbro, Inc. (HAS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Novo Nordisk A/S — how do they compare? Hasbro, Inc. trades at $92.82 (market cap $13.05B), while Novo Nordisk A/S trades at $38.16 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 12.7× Hasbro, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Novo Nordisk A/S for 116 Days on average.
| HAS | NVO | |
|---|---|---|
Market Cap | $13.05B | $165.31B |
Volume | 1,207,655 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $63.98 |
52-Week Low | $70.95 | $35.29 |
Typical Hold Time | 97 Days | 116 Days |
Enterprise Value | $15.24B | $179.56B |
Dividend Yield | 3.03% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $90.75, down 0.31% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates robust profitability with 64.41% gross margins and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains positive with a $107.60 price target, representing 18.5% upside potential from current levels. Recent news highlights continued momentum in the Magic: The Gathering franchise and new product collaborations.
The outlook remains constructive with projected revenue growth to $5.0B in 2026 and net income recovery to $794M. Key risks include high debt levels at 59.09% debt-to-asset ratio and recent net income volatility. The stock offers value with reasonable P/E of 16.14x and strong institutional interest, though investors should monitor Q3 2026 earnings on October 20 for confirmation of the turnaround trajectory.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
